Magnetic Mitohormesis: Effect of Magnetic Signals on Metabolic Adaptions in Type 2 Diabetes (MENSA-T2D)

Sponsor
Singapore General Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05881200
Collaborator
QuantumTX Pte Ltd (Other)
40
1
16

Study Details

Study Description

Brief Summary

Magnetic Mitohormesis (MM) replicates the metabolic and regenerative effects of exercise using an equipment called the BIXEPS machine, which introduces magnetic fields to the thigh muscles in a non-invasive and painless manner. Since exercise improves the blood glucose control of patients with Type 2 Diabetes Mellitus (T2DM), we believe that MM can provide the same benefits.

This single-arm pilot study investigates the effect of MM therapy on glycemic control in individuals with T2DM.

Condition or Disease Intervention/Treatment Phase
  • Device: Magnetic mitohormesis
N/A

Detailed Description

Type 2 diabetes mellitus (T2DM) is becoming a significant health issue in the ageing Singapore population. Exercise has been shown to improve peripheral insulin sensitivity, and exercise interventions are often prescribed alongside medication to manage diabetes. However, patient compliance with diet and exercise intervention regimes can often be challenging.

Magnetic Mitohormesis (MM) is an alternative method of muscle and mitochondria activation. MM sessions are brief 10-minute weekly sessions that recreate similar biological and metabolic adaptations as exercise but without physical stress or strain. MM can be easily applied to any age group while seated and without limitations on users' physical aptitude.

Having MM as an adjunct therapy to exercise and drug interventions could improve glycaemic control in T2DM patients, especially amongst the ageing population and those with less exercise capacity.

This single-arm pilot study investigates the effect of MM therapy on glycemic control in individuals with T2DM.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Magnetic Mitohormesis: Effect of Magnetic Signals on Metabolic Adaptions in Type 2 Diabetes
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Mar 31, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Magnetic mitohormesis

Treatment using the BIXEPS machine

Device: Magnetic mitohormesis
The BIXEPS machine employs gentle pulsed magnetic signals specifically tuned to activate the natural "powerhouse" (mitochondria) within muscle. Brief 10-minute MM sessions with the device recreate similar biological and metabolic effects as exercise, but without physical stress or strain. It is intended to improve the strength and function of users, promoting overall fitness and well-being. Just like exercise, these effects accumulate with time. Subjects will receive 12 sessions of 10 minute treatments

Outcome Measures

Primary Outcome Measures

  1. Change in HbA1C [12 weeks]

    Change in glycemic control

  2. Change in insulin resistance [12 weeks]

    Change in Homeostatic Model Assessment for Insulin Resistance index

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 40-75 years

  2. T2DM of at least 6 months duration

  3. HbA1c between 7.0% - 10.0% (most recent 3-months prior to enrolment)

  4. Body Mass Index (BMI) between 23.0 and 32.5 kg/m2

  5. Able to ambulate independently

  6. Willing and able to give written informed consent

Exclusion Criteria:
  1. Presence of any conditions contraindicated for PEMF exposures (e.g. active electronic implants, pregnancy, pacemakers, implantable defibrillators)

  2. Medical advice against physical activity

  3. Chest pain when performing physical activity

  4. Chest pain at rest

  5. BP > 180/90 mmHg

  6. Women who are lactating, pregnant or considering pregnancy

  7. Cancer not in remission or receiving active cancer treatment

  8. Current participation in another clinical trial

  9. Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)

  10. Uncontrolled thyroid disease

  11. Significant alcohol intake (> 1 unit per day for women and > 2 units per day for men)

  12. Any factors likely to limit adherence to study protocol (e.g. dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other or family members)

  13. Anticipated surgery or changes in diabetes medications during the study duration

  14. History of severe hypoglycaemia in the recent 3 months

  15. Have used the MM device in the past 3 months

  16. Had a recent surgical procedure in the last 6 months, where muscle activation can interfere with the healing response

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Singapore General Hospital
  • QuantumTX Pte Ltd

Investigators

  • Principal Investigator: Hong Chang Tan, Singapore General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Singapore General Hospital
ClinicalTrials.gov Identifier:
NCT05881200
Other Study ID Numbers:
  • MENSA-T2D
First Posted:
May 31, 2023
Last Update Posted:
May 31, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Singapore General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 31, 2023